000280976 001__ 280976
000280976 005__ 20250921002019.0
000280976 0247_ $$2doi$$a10.1016/j.jacadv.2025.102015
000280976 0247_ $$2pmid$$apmid:40706144
000280976 0247_ $$2pmc$$apmc:PMC12309279
000280976 0247_ $$2altmetric$$aaltmetric:179704956
000280976 037__ $$aDZNE-2025-01058
000280976 041__ $$aEnglish
000280976 082__ $$a610
000280976 1001_ $$aGelfert, Gloria G$$b0
000280976 245__ $$aAssociation of Lipoprotein(a) With Cardiovascular and Cerebrovascular Disease in a Nationally Representative Cohort of Germany.
000280976 260__ $$a[Amsterdam]$$bElsevier B.V.$$c2025
000280976 3367_ $$2DRIVER$$aarticle
000280976 3367_ $$2DataCite$$aOutput Types/Journal article
000280976 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1758110381_31850
000280976 3367_ $$2BibTeX$$aARTICLE
000280976 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280976 3367_ $$00$$2EndNote$$aJournal Article
000280976 520__ $$aPopulation-based data on the distribution of lipoprotein(a) (Lp[a]) within the German population are lacking.The aim of the study was to determine the age- and sex-specific Lp(a) distribution in Germany and analyze its association with different types of cardiovascular disease (CVD).We analyzed cross-sectional data from the German National Health Interview and Examination Survey 1998, a population-based study representing the German adult population's health status from 1997 to 1999. We examined serum Lp(a) according to demographics and investigated associations between Lp(a) and history of self-reported CVD. We tested Lp(a) in spline analysis on continuous scales and as dichotomous Lp(a) thresholds.In the German National Health Interview and Examination Survey 1998 (n = 6,657), median Lp(a) was 15.3 mg/dL (Q1-Q3: 5.6, 43.1). Lp(a) levels ≥50 mg/dL were present in 21.6%. Men had substantially higher median Lp(a) than women (22.1 mg/dL vs 10.3 mg/dL). Median Lp(a) levels were significantly higher in individuals with than without a history of atherosclerotic cardiovascular disease (ASCVD) but did not significantly differ between people with and without venous thrombosis. In logistic regression analysis with splines, higher Lp(a) levels were associated with a higher probability of a history of CVD. In logistic regression analyses, Lp(a) ≥50 mg/dL was associated with a history of ASCVD (OR: 1.36 [95% CI: 1.04-1.78]; P = 0.023).About 1 in 5 German individuals from a prestatin era population had Lp(a) levels ≥50 mg/dL. Higher levels were independently associated with ASCVD, but not with venous thrombosis. These findings provide a basis for future prospective studies to define the role of Lp(a) in CVD risk in the German population.
000280976 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000280976 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280976 650_7 $$2Other$$acardiovascular disease
000280976 650_7 $$2Other$$acardiovascular risk
000280976 650_7 $$2Other$$aepidemiology
000280976 650_7 $$2Other$$alipoprotein(a)
000280976 650_7 $$2Other$$aprevention
000280976 650_7 $$2Other$$avenous thrombosis
000280976 7001_ $$aGrittner, Ulrike$$b1
000280976 7001_ $$aKuhnert, Ronny$$b2
000280976 7001_ $$aScheidt-Nave, Christa$$b3
000280976 7001_ $$0P:(DE-2719)2811033$$aEndres, Matthias$$b4$$udzne
000280976 7001_ $$aNave, Alexander H$$b5
000280976 773__ $$0PERI:(DE-600)3169577-2$$a10.1016/j.jacadv.2025.102015$$gVol. 4, no. 8, p. 102015 -$$n8$$p102015$$tJACC: advances$$v4$$x2772-963X$$y2025
000280976 8564_ $$uhttps://pub.dzne.de/record/280976/files/DZNE-2025-01058%20SUP.pdf
000280976 8564_ $$uhttps://pub.dzne.de/record/280976/files/DZNE-2025-01058.pdf$$yRestricted
000280976 8564_ $$uhttps://pub.dzne.de/record/280976/files/DZNE-2025-01058%20SUP.pdf?subformat=pdfa$$xpdfa
000280976 8564_ $$uhttps://pub.dzne.de/record/280976/files/DZNE-2025-01058.pdf?subformat=pdfa$$xpdfa$$yRestricted
000280976 909CO $$ooai:pub.dzne.de:280976$$pVDB
000280976 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811033$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000280976 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000280976 9141_ $$y2025
000280976 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000280976 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000280976 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-03-22T12:36:56Z
000280976 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-03-22T12:36:56Z
000280976 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-03-22T12:36:56Z
000280976 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
000280976 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
000280976 9201_ $$0I:(DE-2719)1811005$$kAG Endres$$lInterdisciplinary Dementia Research$$x0
000280976 980__ $$ajournal
000280976 980__ $$aVDB
000280976 980__ $$aI:(DE-2719)1811005
000280976 980__ $$aUNRESTRICTED